Anti-cancer "Spirocyclic-guanidine Compounds" and Uses Thereof

Case ID:
C16365

Unmet Need / Invention Novelty: Currently available anti-cancer proteasome inhibitors are highly effective against liquid tumors, however, resistance develops. Furthermore, available proteasome inhibitors are not effective against solid tumors. There is an unmet need to develop anti-cancer proteasome inhibitors that overcome these limitations.


Technical Details: Researchers at Johns Hopkins have synthesized novel proteasome inhibitors that are effective against both liquid and solid tumors. The novel proteasome inhibitors target a region of the proteasome untargeted by licensed inhibitors and have superior drug properties relating to structure, stability, solubility, safety, and pharmacokinetics. Additionally, the proteasome inhibitors do not cross the blood brain barrier and therefore have fewer neurological side effects, which limits the therapeutic potential of currently licensed proteasome inhibitors. The proteasome inhibitors demonstrate potent and specific cytotoxicity against several types of cancer-derived cell lines and inhibit proteasome function, resulting in cell death, both in vitro and in vivo. Furthermore, the inhibitors are active against cancer cells that are resistant to other licensed proteasome inhibitors. 


Value Proposition:

  • The proteasome inhibitors have favorable drug properties
  • The inhibitors are effective against both liquid and solid tumors
  • The distinct mechanism of the proteasome inhibitors overcomes drug resistance

Looking for Partners to: Develop & commercialize the technology as novel proteasome inhibitors for the treatment of solid and liquid tumors.


Stage of Development: Pre-Clinical


Data Availability: in vitro & in vivo


Inventors: Richard Roden & Ravi Anchoori

Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
ANTI-CANCER SPIROCYCLIC-GUANIDINE COMPOUNDS AND USES THEREOF PCT: Patent Cooperation Treaty Australia 2021277225   5/18/2021     Pending
ANTI-CANCER SPIROCYCLIC-GUANIDINE COMPOUNDS AND USES THEREOF PCT: Patent Cooperation Treaty Canada 3,183,725   5/18/2021     Pending
ANTI-CANCER SPIROCYCLIC-GUANIDINE COMPOUNDS AND USES THEREOF PCT: Patent Cooperation Treaty European Patent Office 21808794.8   5/18/2021     Pending
ANTI-CANCER SPIROCYCLIC-GUANIDINE COMPOUNDS AND USES THEREOF PCT: Patent Cooperation Treaty United States 17/925,923   11/17/2022     Pending
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Vera Sampels
vsampel2@jhu.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum